Cargando…

Ten-Year Single Institutional Analysis of Geographic and Demographic Characteristics of Patients Treated With Stereotactic Body Radiation Therapy for Localized Prostate Cancer

OBJECTIVES: Stereotactic Body Radiation Therapy (SBRT) offers definitive treatment for localized prostate cancer with comparable efficacy and toxicity to conventionally fractionated radiotherapy. Decreasing the number of treatment visits from over 40 to five may ease treatment burden and increase ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aghdam, Nima, Carrasquilla, Michael, Wang, Edina, Pepin, Abigail N., Danner, Malika, Ayoob, Marilyn, Yung, Thomas, Collins, Brian T., Kumar, Deepak, Suy, Simeng, Collins, Sean P., Lischalk, Jonathan W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947279/ https://www.ncbi.nlm.nih.gov/pubmed/33718117 http://dx.doi.org/10.3389/fonc.2020.616286

Ejemplares similares

Self-Reported Burden in Elderly Patients With Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)
por: Aghdam, Nima, et al.
Publicado: (2020)

Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer
por: Pepin, Abigail N., et al.
Publicado: (2022)

Impact of Age on Patient-Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Pepin, Abigail, et al.
Publicado: (2021)

Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy
por: Pepin, Abigail, et al.
Publicado: (2021)

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15)
por: Aghdam, Nima, et al.
Publicado: (2020)

Patient-Reported Financial Burden Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer
por: Sholklapper, Tamir N., et al.
Publicado: (2022)

Management of Isolated Local Failures Following Stereotactic Body Radiation Therapy for Low to Intermediate Risk Prostate Cancer
por: Aghdam, Nima, et al.
Publicado: (2020)

Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP)
por: Pepin, Abigail, et al.
Publicado: (2020)

Utilization of Patient-Reported Outcomes to Guide Symptom Management during Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer
por: Danner, Malika, et al.
Publicado: (2017)

Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy
por: Carrasquilla, Michael, et al.
Publicado: (2021)

Testosterone as a Biomarker for Quality of Life (QOL) Following Androgen Deprivation Therapy (ADT) and Stereotactic Body Radiotherapy (SBRT)
por: Shah, Sarthak, et al.
Publicado: (2023)

The Impact of Obesity on Patient Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Koneru, Harsha, et al.
Publicado: (2016)

Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?
por: Kataria, Shaan, et al.
Publicado: (2017)

Utilization of Iodinated SpaceOAR Vue™ During Robotic Prostate Stereotactic Body Radiation Therapy (SBRT) to Identify the Rectal–Prostate Interface and Spare the Rectum: A Case Report
por: Conroy, Dylan, et al.
Publicado: (2021)

Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer
por: Gallagher, Lindsey, et al.
Publicado: (2023)

Association of baseline self-reported fatigue with overall survival after stereotactic body radiation therapy for localized prostate cancer
por: Simhal, Rishabh K., et al.
Publicado: (2022)

Lobar Gross Endobronchial Disease Predicts for Overall Survival and Grade 5 Pulmonary Toxicity in Medically Inoperable Early Stage Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy
por: Aghdam, Nima, et al.
Publicado: (2021)

Stereotactic Body Radiation Therapy: A Versatile, Well-Tolerated, and Effective Treatment Option for Extracranial Metastases From Primary Ovarian and Uterine Cancer
por: Aghdam, Nima, et al.
Publicado: (2020)

Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation
por: Repka, Michael C., et al.
Publicado: (2017)

Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Shah, Sarthak, et al.
Publicado: (2021)

Rationale for Utilization of Hydrogel Rectal Spacers in Dose Escalated SBRT for the Treatment of Unfavorable Risk Prostate Cancer
por: Repka, Michael C., et al.
Publicado: (2022)

Long-Term Outcomes Following Conventionally Fractionated Stereotactic Boost for High-Grade Gliomas in Close Proximity to Critical Organs at Risk
por: Repka, Michael C., et al.
Publicado: (2018)

Long-term outcomes of stereotactic body radiation therapy (SBRT) with fiducial tracking for inoperable stage I non-small cell lung cancer (NSCLC)
por: Lischalk, Jonathan W., et al.
Publicado: (2016)

Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Janowski, Einsley-Marie, et al.
Publicado: (2015)

Toxicity After Stereotactic Body Radiation Therapy for Prostate Cancer in Patients With Inflammatory Bowel Disease: A Multi-institutional Matched Case-Control Series
por: Juarez, Jesus E., et al.
Publicado: (2021)

Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity
por: Paydar, Ima, et al.
Publicado: (2017)

Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3))
por: Janowski, Einsley, et al.
Publicado: (2014)

Proctitis 1 Week after Stereotactic Body Radiation Therapy for Prostate Cancer: Implications for Clinical Trial Design
por: Paydar, Ima, et al.
Publicado: (2016)

Clinical Characteristics and Management of Late Urinary Symptom Flare Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Woo, Jennifer A., et al.
Publicado: (2014)

Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer
por: Gurka, Marie K, et al.
Publicado: (2015)

Urethrogram-Directed Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer in Patients with Contraindications to Magnetic Resonance Imaging
por: Paydar, Ima, et al.
Publicado: (2015)

Improved Irritative Voiding Symptoms 3 Years after Stereotactic Body Radiation Therapy for Prostate Cancer
por: Rana, Zaker, et al.
Publicado: (2014)

Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer
por: Arscott, W Tristram, et al.
Publicado: (2014)

Proctitis following stereotactic body radiation therapy for prostate cancer
por: Joh, Daniel Y, et al.
Publicado: (2014)

Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer
por: Bhattasali, Onita, et al.
Publicado: (2014)

Stereotactic body radiotherapy (SBRT) for high-risk central pulmonary metastases
por: Lischalk, Jonathan W., et al.
Publicado: (2016)

Potency preservation following stereotactic body radiation therapy for prostate cancer
por: Obayomi-Davies, Olusola, et al.
Publicado: (2013)

Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction
por: Repka, Michael C., et al.
Publicado: (2016)

Rationale for Stereotactic Body Radiation Therapy in Treating Patients with Oligometastatic Hormone-Naïve Prostate Cancer
por: Bhattasali, Onita, et al.
Publicado: (2013)

Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer
por: Chen, Leonard N, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vgflq5ea4sbismvd6i88oq5dci